Actively Recruiting
A Clinical Trial Evaluating IL-22BP/LNP Compound in Refractory Malignant Solid Tumors for Safety, Tolerability and Activity
Led by Xingchen Peng · Updated on 2025-12-29
6
Participants Needed
1
Research Sites
56 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study aims to investigate the safety and efficacy of the IL-22BP/LNP compound in patients with refractory malignant solid tumors, such as advanced soft tissue sarcoma, advanced head and neck squamous cell carcinoma, and malignant melanoma, who have failed second-line treatment, have advanced recurrence or metastatic malignant solid tumors.
CONDITIONS
Official Title
A Clinical Trial Evaluating IL-22BP/LNP Compound in Refractory Malignant Solid Tumors for Safety, Tolerability and Activity
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male or female patients aged 18 to 70 years old
- Histopathologically confirmed refractory advanced recurrent or metastatic malignant solid tumors, including advanced soft tissue sarcoma, advanced head and neck squamous cell carcinoma, and malignant melanoma
- Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1
- Expected survival time of at least 3 months
- At least 28 days since last chemotherapy, radiotherapy, or surgery
- At least 6 weeks since last use of nitrosoureas or mitomycin C
- Main organ functions are in good condition
- Signed written informed consent form
You will not qualify if you...
- Participation in other drug clinical trials within 4 weeks
- Tumor located near major blood vessels or the trachea
- Uncontrolled cardiac symptoms or diseases, including heart failure NYHA class II or above, unstable angina, recent myocardial infarction within 1 year, or significant arrhythmias requiring treatment
- Pregnant or lactating women
- Active tuberculosis, bacterial or fungal infections grade 2 or higher, active HIV, HBV, or HCV infection
- History of psychotropic drug abuse or mental disorders
- Active autoimmune diseases or history of autoimmune diseases, except vitiligo or childhood asthma fully resolved without intervention
- Current immunosuppressive treatment
- History of drug abuse or known medical, psychological, or social conditions such as alcoholism
- Known allergy or intolerance to IL-22BP/LNP or any excipients, or severe allergy history to drugs, foods, or vaccines
- Pregnancy plans for female subjects or male partners within 12 months after drug injection
- Other serious diseases that endanger safety or study completion as judged by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
West China Hospital of Sichuan University
Chengdu, Sichuan, China, 610041
Actively Recruiting
Research Team
X
Xingchen Peng
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here